Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 9/20 | 0.66 |
| ▸ | SHBG | P04278 | 8/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.66 |
| ▸ | SERPINA6 | P08185 | 7/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | TSHR | P16473 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.66 |
| ▸ | PGR | P06401 | 3/20 | 0.66 |
| ▸ | AR | P10275 | 3/20 | 0.66 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671789 | 0.89 | LMNA (0.69) | LMNASHBGSMN1; SMN2SERPINA6CYP3A4 | |
| SCHEMBL7242829 | 0.81 | LMNA (0.58) | LMNASHBGSMN1; SMN2SERPINA6CYP3A4 | |
| SCHEMBL6840982 | 0.81 | CYP3A4 (0.55) | LMNASHBGSMN1; SMN2SERPINA6CYP3A4 | |
| SCHEMBL6840979 | 0.81 | CYP3A4 (0.55) | LMNASHBGSMN1; SMN2SERPINA6CYP3A4 | |
| Progesterone SCHEMBL11659276 | 0.80 | CYP3A4 (0.95) | LMNASHBGSMN1; SMN2SERPINA6CYP3A4 | |
| Progesterone SCHEMBL23568915 | 0.80 | CYP3A4 (1.00) | LMNASHBGSMN1; SMN2SERPINA6CYP3A4 | |
| Progesterone SCHEMBL15224316 | 0.80 | CYP3A4 (1.00) | LMNASHBGSMN1; SMN2SERPINA6CYP3A4 | |
| Progesterone SCHEMBL8430168 | 0.80 | CYP3A4 (1.00) | LMNASHBGSMN1; SMN2SERPINA6CYP3A4 | |
| Progesterone SCHEMBL20409003 | 0.80 | CYP3A4 (1.00) | LMNASHBGSMN1; SMN2SERPINA6CYP3A4 | |
| Progesterone SCHEMBL13259536 | 0.80 | CYP3A4 (1.00) | LMNASHBGSMN1; SMN2SERPINA6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586080-B1 | Inhibiting crystallization of steroidal hormones in transdermal delivery systems | NOVEN PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20100047345-A1 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM FOR HYDROMORPHONE | CROWLEY MICHAEL M | 2010-02-25 | — | — | US | disclosed |
| EP-2068840-A2 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM | LAB International SRL (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-2049087-A2 | HYDROPHILIC ABUSE DETERRENT DELIVERY SYSTEM | LAB International SRL (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080075770-A1 | HYDROPHILIC ABUSE DETERRENT DELIVERY SYSTEM | AKELA PHARMA SRL (BB) | 2008-03-27 | — | — | US | disclosed |
| US-20080075768-A1 | HYDROPHOBIC OPIOID ABUSE DETERRENT DELIVERY SYSTEM USING OPIOID ANTAGONISTS | AKELA PHARMA SRL (BB) | 2008-03-27 | — | — | US | disclosed |
| US-20080069871-A1 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM | AKELA PHARMA SRL (BB) | 2008-03-20 | — | — | US | disclosed |
| US-20080063698-A1 | Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use | NOVEN PHARMACEUTICALS, INC. | 2008-03-13 | — | — | US | disclosed |
| WO-2008011595-A9 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM | LAB INTERNAT SRL (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008011596-A2 | HYDROPHILIC ABUSE DETERRENT DELIVERY SYSTEM | LAB INTERNATIONAL SRL (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20040142023-A1 | Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use | NOVEN PHARMACEUTICALS, INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004050066-A1 | MICROSPHERES AND RELATED PROCESSES AND PHARMACEUTICAL COMPOSITIONS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-6638528-B1 | Pressure-sensitive adhesive matrix comprising blend of polyacrylate, polysiloxane, polyisobutylene, polyisoprene, polyamide or polystyrene; and insoluble, non-adhesive ethyl cellulose; polyvinylpyrrolidone crystallization inhibitor | NOVEN PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| US-20030152616-A1 | Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6465004-B1 | ESTERIFIED OR ACYLATED CELLULOSE TO STABILIZE THE CONCENTRATION OF THE ACTIVE AGENT IN THE COMPOSITION AND TO INHIBIT CRYSTAL FORMATION; PRESSURE-SENSITIVE ADHESIVE CARRIER; CELLULOSE ACETATE BUTYRATE | NOVEN PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | disclosed |
| US-20020106402-A1 | Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use | NOVEN PHARMACEUTICALS, INC. | 2002-08-08 | — | — | US | disclosed |
| WO-2002045701-A2 | CRYSTALLIZATION INHIBITION OF DRUGS IN TRANSDERMAL DRUG DELIVERY SYSTEMS | NOVEN PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| US-20020004065-A1 | Compositions and methods to effect the release profile in the transdermal administration of active agents | KANIOS DAVID (US) | 2002-01-10 | — | — | US | disclosed |
| WO-2001052823-A2 | COMPOSITIONS TO EFFECT THE RELEASE PROFILE IN THE TRANSDERMAL ADMINISTRATION OF DRUGS | NOVEN PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2000074661-A2 | SOLUBILITY ENHANCEMENT OF DRUGS IN TRANSDERMAL DRUG DELIVERY SYSTEMS AND METHODS OF USE | NOVEN PHARMACEUTICALS, INC. (US) | 2000-12-14 | — | — | WO | disclosed |